The UK’s first one-stop kidney cancer clinic at @CUH_NHS is transforming kidney cancer diagnosis. With a confocal microscope, patients can get a biopsy, diagnosis & treatment plan – all on the same day. Find out more: https://t.co/p9xiJUqTxX @CRUKCamUrol @ACTcharity

🚨 We’re looking for an Academic Clinical Fellow in Urology ST1/2 level. An exciting opportunity to join @Cambridge_Uni, contribute to cutting-edge research + develop your clinical career. 📍Cambridge 🗓️ Applications open now via Oriel: 👉

Read the full paper here:

The third blog in our series on INKCC is out now: recommendations for assessing pathological response in neoadjuvant kidney cancer trials Read more 👇 https://t.co/xLSHcLa54y

🚨 New blog: Our researchers publish new data demonstrating the prevalence of kidney cancer in high-risk individuals, using data from our @yorkshirecancer funded kidney screening trial. Read more 👉 https://t.co/CzKxaPfkMJ

ICYMI, here's our introduction to INKCC:

We've just shared the second blog in our series about the work of the International Neoadjuvant Kidney Cancer Consortium (INKCC), a group of experts building international strategy in research on neoadjuvant therapies for patients with kidney cancer: https://t.co/1IhMKpvEDB

Congratulations to Harveer and Simon on publishing outcomes from their CANCAP study

Congratulations @Tom_J_Mitchell on winning the Christopher G Wood Rising Star Award at #IKCSEU2025 earlier this month - very well deserved!

Findings published in @EUplatinum suggest that the combined screening approach is feasible and of potential benefit: https://t.co/5Ac7pZeSvT  (6/6)

When @YorkshireKST provided an additional upper abdominal CT scan for 4,019 people attending lung-cancer screening (funded by @yorkshirecancer), the study identified: 🚩10 new cases of kidney cancer 🔍10 other abdominal cancers 📈60 new abdominal aortic aneurisms. (5/6)

The analysis concludes that considering all relevant diseases in screening models is vital for developing cost-effective screening programmes. It also recommends a larger trial, which is currently in development by the UMVI with funding from @yorkshirecancer. (4/6)

The analysis considered detection of other conditions alongside kidney cancer, with the detection of abdominal aortic aneurysm the leading contributor to the cost-effectiveness of the screening programme. (3/6)

A paper, published in @BrJCancer, shows that adding an upper abdominal CT scan to the thoracic CT scan offered within the lung cancer screening programme has a 96% probability of being cost-effective: https://t.co/VZJVJMs4Hf (2/6)

New analysis by @SCHARRSheffield, in collaboration with UMVI researchers, using data from our world-first Yorkshire Kidney Screening Trial, shows that screening for kidney cancer is potentially cost effective. Read more: https://t.co/VZJVJMs4Hf (1/6)

Rebecca Wray, joint first author on this paper, presented her work at the @AACR Annual Meeting this weekend

Using a machine learning model to analyse data from the NAXIVA trial, @CRUKCamUrol members have discovered early markers of response in patients treated for kidney cancer with venous tumour thrombus using a drug called axitinib. @NatureComms Read more: https://t.co/EzNHjHlTWp

This work demonstrates how translational work is a vital part of clinical trials and shows the potential of AI and machine learning for finding relevant insights within huge datasets. Read more at our blog 👉 https://t.co/0DZ0lP316U

Joint first author and AI developer Rebecca Wray said that this translational work addresses a question ‘crucial’ to patient care – why some patients respond and others don’t.

Dr Jones and colleagues analysed blood and tumour samples from patients in NAXIVA, then used a machine learning model to unpick which factors were driving response in each patient. They found that placental growth factor levels in the blood can be used to predict response